Cambridge Isotope Laboratories (CIL), a global leader in stable isotope chemistry and a subsidiary of Otsuka Pharmaceutical (Japan), has launched ISOAPI-D, a unified brand of deuterated intermediates for active pharmaceutical ingredient (API) synthesis, at CPhI Frankfurt. 

The new ISOAPI-D range provides pharmaceutical partners with a secure, global supply of deuterated reagents manufactured to the highest quality standards, designed to support faster and more efficient API development.

Cliff Caldwell, CEO of CIL, said, "ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation. With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materials they need for robust and efficient drug development."

A core component of the ISOAPI-D line is heavy water (D?O), sourced exclusively from approved suppliers. Fully traceable and tritium-free, the product meets stringent pharmaceutical safety and regulatory standards. The range also includes advanced intermediates that streamline synthetic pathways, reduce synthesis steps, and enhance production efficiency — helping lower manufacturing costs and accelerate time-to-market for new therapeutics.

Tasha Agreste, Business Development Manager Deuterated Reagent Applications, at CIL, added, "ISOAPI-D represents the next step in our ongoing mission to support pharmaceutical innovation. Our expanded manufacturing capabilities, rigorous quality standards, and decades of experience position CIL as a reliable partner for the industry's evolving needs."

CIL’s global manufacturing network, spanning North America, Europe and Asia, ensures a diversified and resilient supply chain for pharmaceutical clients.